RecruitingNot ApplicableNCT07486791

A Clinical Study on the Effect of Cardiopulmonary Function and Quality of Life in Patients With Acute Coronary Syndrome Complicated by Heart Failure by "Lying-Sitting-Standing" Sequential Baduanjin

Sponsor

Xiling Qi

Enrollment

65 participants

Start Date

Mar 10, 2026

Study Type

INTERVENTIONAL

Conditions

ACS (Acute Coronary Syndrome)HF - Heart Failure

Summary

This study investigates the effects of a sequential "lying-sitting-standing" Baduanjin intervention on patients with acute coronary syndrome complicated by heart failure. By evaluating cardiopulmonary function and quality of life through indicators such as echocardiography, NT-proBNP, 6MWT, NYHA classification, and SF-36, we aim to compare its efficacy with conventional treatment. The objective is to provide new insights for early cardiac rehabilitation strategies in patients with acute coronary syndrome complicated by heart failure

Eligibility

Max Age: 85 Years

Inclusion Criteria6

Patients meeting the diagnostic criteria for ACS (including unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction)
Complicated by heart failure during hospitalization
Age ≤ 85 years
Muscle strength ≥ grade 3
No history of mental illness, conscious and able to cooperate independently with this study
Voluntarily participate in this study and sign the informed consent form

Exclusion Criteria7

Patients with persistent heart failure symptoms or NYHA functional class IV despite optimal pharmacological therapy;
Patients with contraindications to cardiac rehabilitation, such as uncontrolled hypertension, uncontrolled arrhythmias, or hemodynamic instability;
Patients with untreated structural heart disease, such as heart failure caused by valvular heart disease or congenital heart disease;
Patients in the acute phase of various diseases, such as severe infection, deep vein thrombosis, or severe hepatic or renal failure;
Patients with disabilities, bone or joint diseases, or neurological disorders that preclude participation in Baduanjin exercises;
Patients with a life expectancy of less than one year;
Patients currently participating in other clinical trials.